1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 34.38K | 325.65% |
| Gross profit | -2.07M | 25,674.57% |
| Net profit | -2.06M | 44.08% |
| EBITDA | -2M | 12.87% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.25M |
Number of shares | 342.5M |
52-week high/low | €0.70 - €0.0124 |
| Dividends | No |
Beta | 2.65 |
P/E ratio | -0.78 |
PEG ratio | 0.00 |
P/B ratio | 3.73 |
P/S ratio | 37.08 |
Company profile
Immunovia AB (publ), ein Diagnostikunternehmen, entwickelt und vermarktet Bluttests in Schweden und international. Zu den Produkten des Unternehmens gehört IMMray PanCan-d, ein blutbasierter Test zur Früherkennung von Bauchspeicheldrüsenkrebs. Außerdem entwickelt es Forschungsprojekte für Lungenkrebs. Immunovia AB (publ) wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Lund, Schweden.
| Name | Immunovia AB |
| CEO | Jeff Borcherding |
| Headquarters | Lund,
sn Sweden |
| Website | |
| IPO | 12/01/2015 |
| Employees | 13 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Sto | IMMNOV.ST |
London Stock Exchange | 0G8X.L |
Pnk | IMMVF |
Frankfurt | 1YR.F |
London | 0G8X.L |
Stockholm | IMMNOV.ST |
München | 1YR.MU |
Discover assets
Shareholders of Immunovia AB also invest in the following assets
